Nuclear fusion holds immense potential for clean energy. As long-term investors, Baillie Gifford recognized this potential and, in June 2021, invested in SHINE Technologies. They recently interviewed our CEO, Greg Piefer, to learn more about SHINE's approach.
At SHINE, we take a unique step-by-step approach, focusing on practical applications today, not just distant dreams. That's how we prioritize profitability along the journey to fusion innovation.
Unlike traditional nuclear companies, SHINE adopts a bottom-up, first-principles approach, questioning constraints and engineering innovative, safe, and cost-effective solutions. This approach fosters nimbleness and commercial viability, setting the stage creating an achievable path to profitability by 2024.
Our fusion tech is already transforming the medical industry, producing isotopes for cancer diagnosis and therapy. Soon, we'll be the world's largest producer.
But the real game-changer? Our transmutation process—recycling nuclear waste and radioisotopes that are difficult or impossible to dispose of. Transmutation turns them into valuable, stable isotopes--which means we're not just addressing billion-dollar markets; we're eyeing multi-trillion-dollar opportunities.
Fusion power will reshape the world, and SHINE is leading the way.
Read the full interview between Luke Ward, Investment Manager at Baillie Gifford, and Greg Piefer, SHINE CEO HERE!
